IL58673A - Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
IL58673A
IL58673A IL58673A IL5867379A IL58673A IL 58673 A IL58673 A IL 58673A IL 58673 A IL58673 A IL 58673A IL 5867379 A IL5867379 A IL 5867379A IL 58673 A IL58673 A IL 58673A
Authority
IL
Israel
Prior art keywords
isolation
membrane proteins
neisseria meningitidis
containing same
vaccines containing
Prior art date
Application number
IL58673A
Other languages
English (en)
Other versions
IL58673A0 (en
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL58673A0 publication Critical patent/IL58673A0/xx
Publication of IL58673A publication Critical patent/IL58673A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL58673A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same IL58673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

Publications (2)

Publication Number Publication Date
IL58673A0 IL58673A0 (en) 1980-02-29
IL58673A true IL58673A (en) 1983-02-23

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL58673A IL58673A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (cg-RX-API-DMAC10.html)
JP (1) JPS5566519A (cg-RX-API-DMAC10.html)
AT (1) ATE857T1 (cg-RX-API-DMAC10.html)
AU (1) AU533386B2 (cg-RX-API-DMAC10.html)
CA (1) CA1142083A (cg-RX-API-DMAC10.html)
DE (2) DE2848965A1 (cg-RX-API-DMAC10.html)
DK (1) DK154841C (cg-RX-API-DMAC10.html)
ES (1) ES485715A1 (cg-RX-API-DMAC10.html)
IL (1) IL58673A (cg-RX-API-DMAC10.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
EP0127681B1 (en) * 1982-12-02 1993-03-03 The Rockefeller University Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 組合わせの髄膜炎菌b/cワクチン
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BR0107679A (pt) 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
BR112014031386A2 (pt) 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
EP3110442B1 (en) 2014-02-28 2020-10-14 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ,インコーポレーテッド 細菌の細胞外小胞
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
CA1142083A (en) 1983-03-01
DK475779A (da) 1980-05-12
AU533386B2 (en) 1983-11-24
JPS5566519A (en) 1980-05-20
IL58673A0 (en) 1980-02-29
EP0011243B1 (de) 1982-04-14
DE2962526D1 (en) 1982-05-27
DK154841C (da) 1989-06-05
ATE857T1 (de) 1982-04-15
JPS6350332B2 (cg-RX-API-DMAC10.html) 1988-10-07
AU5268279A (en) 1980-05-15
ES485715A1 (es) 1980-05-16
EP0011243A1 (de) 1980-05-28
DE2848965A1 (de) 1980-05-22
DK154841B (da) 1988-12-27

Similar Documents

Publication Publication Date Title
DE2962526D1 (en) Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
ATE195420T1 (de) Methode zur herstellung von eicosapentansäuren
DE69224124D1 (de) Verfahren zur Herstellung von Dihomo-Gamma-Linolensäure und das in dieser enthaltende Lipid
HUT50863A (en) Amperometric process for quantitative statement of 1,4 dihydronicotinamid adenin dinucleotid /nadh/ in solution
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
HUT44422A (en) Method and apparatus for improving the quality of roasted coffee
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
YU183587A (en) Process for obtaining liquid ethanole extract of propolis
EP0607593A3 (de) Verfahren zur Gewinnnung von Zellkulturen mit erhöhtem Gehalt an körpereigenen Zytokinen.
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
FR2620726B1 (fr) Procede de preparation d'un extrait de jasmin et extrait obtenu
DE3366707D1 (en) Preparation of glucose dehydrogenase
EP0281978A3 (en) Inactivation of human immunodeficiency virus (hiv) in proteinic solutions by means of phenol
DE3565535D1 (en) Process for the preparation of optically active 1,4-dihydropyridines
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
SU1515606A1 (ru) Способ очистки и выделения нитропруссида натрия
GR3003137T3 (en) Process for the preparation of polychlorophosphazene
MY102317A (en) Novel microorganisms and a method for production of glutamic acid using the same.
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid
UA14449A1 (uk) Спосіб отримаhhя паhтокриhа для іh'єкцій
JPS5682095A (en) Purification of fatty acid produced through fermentation process
JPS55102497A (en) Treatment of waste water containing thiocyanogen
NZ191502A (en) Wood treatment process to eliminate defects using aqueous alkylamine solution

Legal Events

Date Code Title Description
HP Change in proprietorship
KB Patent renewed